Dr. Martin Pfister

Dr. Martin Pfister

Dr. Martin Pfister studied medicine and pharmacy at the University of Greifswald and New York University and received his doctorate in immunology. He worked in various academic laboratories. Since 2000 he has been active in the start-up scene. He took over management positions and is co-founder of two successful companies in the fields of diagnostics & health services. In 2010 he transferred to the HTGF on the investor side. With his long-standing experience in drug development/gene therapy and medical technology/diagnostics, he is a valued sparring partner for portfolio companies in the fields of biotechnology and healthcare. He also holds several advisory board positions with portfolio companies.


+49 – (0)228 – 82300 – 123



13. September 2021
RESI Partnering Week | Life Science Nation
Life Science Nation (LSN) is bringing back Redefining Early Stage Investments Partnering Week (RPW), a 1-week partnering event on September 13-17th, 2021. Format: digital This time, RESI Partnering Week will host three digital partnering conferences: Redefining Early Stage Investments (RESI), RESI AI, and RESI Longevity. These  conferences function as an early-stage fundraising trifecta, giving start ups opportunities to network with investors and strategic partners based on product fit and s

Posts & mentions

25. August 2021

Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion Hanover, Germany, August 25, 2021 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, announced today the closing of a €64 million ($76 million) Series B financing round. The round was led by Inkef Capital, supported by fello
2. August 2021

Successful exit for High-Tech Gründerfonds – HTGF fund investor Evonik acquires biotech company JeNaCell

Acquisition of JeNaCell expands Evonik’s portfolio of biomaterials used in medical technologyJeNaCell to realize full potential of its innovative technology and further expand its technology portfolio with Evonik’s supportHigh-Tech Gründerfonds (HTGF) financed the seed round in 2012 together with the Foundation for Technology, Innovation and Research Thuringia (STIFT)bm|t acquired stake in JeNaCell in 2015 together with Sparkasse Jena-Saale-Holzland and HTGF fund investor Evonik Venture
26. January 2021

GeneQuine Biotherapeutics Secures more than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases

Proceeds will facilitate development of GeneQuine’s gene therapy pipeline for musculoskeletal disorders and vector platformLead gene therapy candidate GQ-303, a potentially disease-modifying treatment for osteoarthritis, will be advanced to Phase 1 clinical trialGene therapy program for intervertebral disc degeneration will be acceleratedCompany is expanding with additional site and staff GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for mu
17. November 2020

lino Biotech closes seed financing round and showcases a novel label-free biosensor platform for innovate modern drug screening

After almost a decade of initial invention and joint research on the Focal Molography technology at Roche, a leading player in the diagnostics and pharmaceutical area, and ETH Zurich as one of Europe’s most renowned research institutes, lino Biotech AG has licensed the technology to further develop and commercialize Focal Molography. The company has received 7-digit financing from lead-investors HTGF, Roche Ventures and several family offices. This broadly patented technology offers lab
3. June 2020

Innovative Pulsatile Heart Pumps for Acute Patients: NovaPump secures seven-digit Financing Round

NovaPump, one of the leading developers and medical product manufacturers of percutaneous circulatory mechanical support systems (pMCS) announced the successful closing of a series A financing round with a consortium of institutional and strategic investors. NovaPump’s PERKAT™ (PERkutane KATheterpumpe) short term MCS for acute patients achieved important milestones within the last months. With this financing round it is possible to develop the PERKAT™ products further to the first-i